On this date, the World Health Organization (WHO) was informed of cases of pneumonia of unknown cause in Wuhan, China. This early alert triggered international disease surveillance and set off the scientific and logistics race that later included manufacturing, global allocation, and vaccine cold-chain distribution.
WHO described the outbreak as a pandemic, signaling sustained global spread. This intensified demand for medical countermeasures and accelerated planning for worldwide vaccine manufacturing and delivery capacity, including specialized cold-chain systems.
Global health partners launched the Access to COVID-19 Tools (ACT) Accelerator to speed development and expand access to tests, treatments, and vaccines. It created an organizing framework for funding, procurement, and delivery planning that later supported cross-border vaccine supply chains.
The U.S. government announced Operation Warp Speed to accelerate vaccine development, manufacturing, and distribution. Its approach—funding production early and planning distribution in parallel—highlighted how supply-chain decisions were becoming as important as laboratory research.
At the Global Vaccine Summit, the Gavi COVAX Advance Market Commitment (AMC) launched to help lower-income economies access COVID-19 vaccines. Gavi also reports AstraZeneca as the first manufacturer to sign up to the COVAX Facility, an early step toward pooled procurement and planned global distribution.
The United Kingdom started a national vaccination program using the Pfizer-BioNTech vaccine, with Margaret Keenan among the first recipients. The rollout demonstrated real-world constraints of vaccine distribution, including scheduling, last-mile delivery, and ultra-cold storage requirements.
UNICEF, acting as COVAX’s procurement coordinator and procurement agent, launched a dashboard to track vaccine development, production capacity, and supply agreements. This transparency tool reflected how vaccine access depended on manufacturing contracts, delivery schedules, and cold-chain capacity—not only on scientific success.
WHO issued an Emergency Use Listing (EUL) recommendation for the Pfizer-BioNTech vaccine (Comirnaty). The EUL was a key step for UN agencies and COVAX to procure and supply vaccines internationally, connecting regulatory decisions directly to global logistics flows.
Pfizer described that early labels required storage around -80°C to -60°C, with shipping in thermal containers refilled with dry ice. These requirements shaped global cold-chain logistics, forcing investments in freezers, temperature monitoring, trained handling, and contingency planning for transport delays.
Ghana received the first shipment of vaccines distributed by COVAX, marking a major shift from planning to large-scale international delivery. The event tested end-to-end logistics—airport handling, customs, refrigerated storage, and distribution to priority groups—under real conditions.
WHO listed Moderna’s mRNA vaccine (mRNA-1273) for emergency use, expanding the portfolio available to global purchasers. WHO noted it is shipped frozen but can also be kept refrigerated (2–8°C) for a limited time, which affected storage planning and distribution options.
A shipment to Rwanda included COVAX’s 1 billionth vaccine dose, showing that supply constraints had eased enough for sustained high-volume international delivery. The milestone also underscored ongoing gaps in coverage and the continuing need to convert shipments into vaccinations through reliable cold-chain and last-mile systems.
Global COVID-19 Vaccine Supply Chains and Cold-Chain Logistics (2019–2022)